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Published by Elsevier Inc.CORRECTIONSchooling CM, Au Yeung SL, Freeman G. Mendelian randomization estimates may be inﬂated. J Am Coll Cardiol
2013;61:1931.
One of the author’s names was misspelled as: Shiu Lun Yeung. The correct spelling is as follows:
Shiu Lun Au Yeung
We apologize for this error.
http://dx.doi.org/10.1016/j.jacc.2014.04.007
CORRECTIONO’Malley RG, Bonaca MP, Scirica BM, Murphy SA, Jarolim P, Sabatine MS, Braunwald E, Morrow DA. Prognostic
performance of multiple biomarkers in patients with non–ST-Segment elevation acute coronary syndrome: analysis
from the MERLIN-TIMI 36 trial (Metabolic Efﬁciency With Ranolazine for Less Ischemia in Non_ST-Elevation
Acute Coronary Syndromes–Thrombolysis In Myocardial Infarction 36). J Am Coll Cardiol 2014;63:1644–53.
In the Results section of the Abstract:
A high concentration (quartile 4 vs. quartiles 1 to 3) of each biomarker identiﬁed an increased risk of CV death or HF
(copeptin: 13.2% vs. 5.0%, p > 0.001; MR-proADM: 15.8% vs. 4.1%, p > 0.001; MR-proANP: 17.7% vs. 3.5%, p > 0.001)
as well as CV death, HF, and myocardial infarction individually (all p  0.001).
and
These biomarkers improved prognostic discrimination and patient re-classiﬁcation for CV death or HF at 1 year
(all categorical NRI <10%, p > 0.001), and maintained independent association with composite CV death or HF when
concurrently assessed in a model with clinical indicators plus BNP, cTnI, ST2, PAPP-A, and MPO (each p0.01).
Should have been:
A high concentration (quartile 4 vs. quartiles 1 to 3) of each biomarker identiﬁed an increased risk of CV death or HF
(copeptin: 13.2% vs. 5.0%, p < 0.001; MR-proADM: 15.8% vs. 4.1%, p < 0.001; MR-proANP: 17.7% vs. 3.5%, p < 0.001)
as well as CV death, HF, and myocardial infarction individually (all p  0.001).
and
These biomarkers improved prognostic discrimination and patient re-classiﬁcation for CV death or HF at 1 year
(all categorical NRI >10%, p < 0.001), and maintained independent association with composite CV death or HF when
concurrently assessed in a model with clinical indicators plus BNP, cTnI, ST2, PAPP-A, and MPO (each p  0.01).
The symbols were inadvertently changed during the ﬁnal production of the manuscript before transmission to the publisher.
We apologize for this error.
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